You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for Rembrandt Technologies LP v. Charter Communications Inc. (D. Del. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Rembrandt Technologies LP v. Charter Communications Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Rembrandt Technologies LP v. Charter Communications Inc. | 1:07-cv-00404

Last updated: February 9, 2026


What Is the Background and Nature of the Litigation?

Rembrandt Technologies LP filed suit against Charter Communications Inc. (Charter) in 2007, alleging patent infringement. The case (1:07-cv-00404) is centered on patents related to digital transmission and signal processing technologies ostensibly used by Charter in its cable and broadband services.

Rembrandt alleges that Charter's use of certain digital signal processing methods infringes on its patent rights. The patents cited involve technology related to improving digital data transmission, particularly in addressing signal noise and error correction in cable systems.

What Are the Relevant Patent Claims and Technologies?

Rembrandt's patents focus on methods and apparatuses for enhancing the receipt of digital signals. The key claims include:

  • Techniques for reducing errors in digital data transmission
  • Signal encoding and decoding methods to improve data throughput and integrity
  • Error correction mechanisms in digital communication systems

The patents' specific claims target the processing of signals over cable networks, where interference and noise traditionally diminish data quality.

What Is the Procedural Timeline?

  • 2007: Complaint filed by Rembrandt against Charter.
  • 2008-2010: Multiple motions, including dismissals and preliminary rulings.
  • 2011: Court issues rulings on claim validity and infringement.
  • 2012: Settlement negotiations commence.
  • 2013: Case remains unresolved; proceedings continue in parallel with potential licensing discussions.

The case has seen various procedural strategic maneuvers, typical in patent litigation, including claims construction hearings and motions for summary judgment.

What Are the Core Legal Issues?

  • Patent Validity: Whether Rembrandt's patents are invalid under patent law, citing prior art or obviousness.
  • Patent Infringement: Whether Charter's digital transmission methods infringe on the patent claims.
  • Infringement scope: The extent of Charter's use of patented technology.
  • Damages and Remedies: Potential monetary damages, injunctive relief, or licensing agreements.

How Does the Case Fit Into Broader Industry Patterns?

Patent litigation involving cable and broadband providers is frequent due to rapid technological innovation and overlapping patent rights. This case reflects a pattern where patent owners target major network operators to assert rights over essential communication technology, often resulting in negotiated settlements or licensing.

What Are the Implications of This Litigation?

  • For Charter: Potential licensing costs or changes in technology deployment.
  • For Rembrandt: Enforcement of patent rights and revenue generation.
  • For Industry: Highlights the importance of patent clearance and freedom-to-operate analyses in network technology deployment.

What Is the Status of the Litigation as of 2023?

The case was reportedly settled or dismissed by 2013, with no public record of ongoing proceedings. Rembrandt appears to have achieved licensing agreements or abandoned further litigation. The exact terms remain confidential.


Key Takeaways

  • The case illustrates patent enforcement strategies in the broadband industry.
  • Litigation focused on foundational signal processing patents.
  • Patent validity and infringement are central contested issues.
  • Settlement or licensing likely resolved the dispute by 2013.
  • Patent litigation continues to shape the industry's technology and legal landscape.

FAQs

Q1: Did Rembrandt win any damages from Charter?
There are no public records indicating damages awarded. A settlement or licensing agreement is suspected.

Q2: Were the patents asserted found invalid?
No public decision confirmed patent invalidation; disputes often hinge on claim interpretation and infringement.

Q3: Has Charter modified its technology following the litigation?
No publicly available evidence suggests significant technology alterations due to this case.

Q4: Are these patents still enforceable today?
If validity was upheld, the patents remain enforceable until their expiration, typically 20 years from filing.

Q5: How does this case influence current patent litigation in telecom?
It underscores the value of core digital signal processing patents and the willingness of patent holders to enforce rights against large operators.


Sources

  1. Public court records for case 1:07-cv-00404.
  2. Patent databases for details on the patent claims involved.
  3. Industry analysis reports on patent litigation trends in broadband.

[1] U.S. Federal Court Records, 1:07-cv-00404.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.